Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Q4 2025 Annual earnings

Reported January 28, 2026 · Before market open

Revenue$13.6MBeat by $177.9K
EPS-$0.82Beat by $0.02
Revenue estimate$13.4M
EPS estimate-$0.84

Next report

Oct 8, 2026 (in 2 months)
Revenue estimate$19.2M
EPS estimate-$0.65

Financials

Q4 2025

Income statement

See full
Revenue$13.6M+2.2%
Operating income-$83.1M-28.5%
Net income-$78.2M-33.6%
EPS (diluted)-$0.83-10.7%

Balance sheet

See full
Cash & equivalents$247.9M+124%
Total debt$55.7M+96.9%
Total equity$538.7M+2.2%
Total assets$688.1M+2.8%

Cash flow

See full
Operating cash flow-$67.8M-39.1%
CapEx$5.1M+144%
Free cash flow-$73.0M-43.5%

Valuation & ratios

Valuation

as of 11/30/25
See full
Market cap$1.79B+11.4%
Enterprise value$1.6B+4.8%
P/S21.3×-8.2×

Profitability

See full
Operating margin-340.2%-38.9pp
Net margin-314.9%-31.9pp
FCF margin-313.7%-17.5pp

Returns & leverage

See full
Return on equity-49.6%-3.1pp
Debt / equity0.1×0.0×
Current ratio7×+0.6×

FAQ

When did Nurix Therapeutics, Inc. report Q4 2025 earnings?
Nurix Therapeutics, Inc. (NRIX) reported Q4 2025 earnings on January 28, 2026 before market open.
What were Nurix Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Nurix Therapeutics, Inc. reported revenue of $13.6M and eps of $-0.82 for Q4 2025.
Did Nurix Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $13.4M by $177.9K. EPS beat the consensus estimate of $-0.84 by $0.02.
How did Nurix Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.2% from $13.3M a year earlier and eps declined 9.3% from $-0.75.
Where can I find Nurix Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001549595-26-000013) and the 10-K periodic report (0001549595-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.